Table 1.

Therapeutic Development of Carbon Monoxide

Clinical Trial	Status	Description/Indication	CO Delivery Modality	Sponsor	NCT/Publication
Phase 1	Completed	Single Dose Safety	Inhaled	Ikaria/iNO	Mahan52
Phase 1	Completed	Repeat Dose (10d) Safety	Inhaled	Ikaria/iNO	Mahan52
Phase 1	Completed	Single Dose Safety	CORM*	Prolong	Misra78
Phase 1	Completed	Lung Inflammation	Inhaled	Academic	NCT00094406
Phase 1	Completed	Mitochondrial Biogenesis	Inhaled	Academic	Rodes79
Phase 1	Completed	Experimental Shock	Inhaled	Academic	Mayr80
Phase 1	Completed	Headache/Migraine	Inhaled	Academic	NCT02066558
Phase 1	Completed	Lung Vascular Function	Inhaled	Academic	NCT03067701
Phase 1	Completed	Retinal Blood Flow	Inhaled	Academic	Resch81
Phase 1	Completed	Regulation of Chemoreflex	Inhaled	Academic	Vesely82
Phase 1b	Completed	SCD	Inhaled	Academic	Sirs83
Phase 1b	Completed	SCD	Inhaled	Academic	Beutler84
Phase 1b	Completed	SCD	CORM*	Sangart	Howard
Phase 1b	Completed	SCD	CORM*	Prolong	NCT01848925
Phase 1b	Completed	ARDS	Inhaled	Academic	NCT02425579
Phase 1b	Completed	End Stage Renal Disease	CORM*	Prolong	NCT02437422
Phase 1b	Completed	Headache/Migraine	Inhaled	Academic	NCT03385174
Phase 1b	Completed	Migraine Inducing Effects	Inhaled	Academic	NCT03075020
Phase 2	Completed	COPD	Inhaled	Academic	NCT00122694
Phase 2	Completed	IPF	Inhaled	Academic	NCT01214187
Phase 2	Completed	SCD - VoC	CORM*	Prolong	NCT02672540
Phase 2	Completed	SCD - VoC	CORM*	Prolong	NCT02411708
Phase 2	Completed	Subarachnoid Hemorrhage	CORM*	Prolong	NCT02323685
Phase 2	Completed	SCD-ulcer	CORM*	Prolong	NCT02600390
Phase 2/3	Completed	Kidney Transplant	CORM*	Prolong	NCT02490202
Phase 2	Ongoing	ARDS	Inhaled	Academic	NCT03799874

SCD, sickle cell disease; COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; VoC, vasooclussive crisis;, ARDS, acute respiratory distress syndrome; NCT, national clinical trial (www.clinicaltrials.gov).

^*Pegylated Hemoglobin